Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nectar Allergy Drops are a form of personalized sublingual immunotherapy (SLIT) developed by Nectar Life Sciences for treating moderate to severe indoor and outdoor environmental allergies. [2, 12] The treatment is custom-formulated for each patient based on the results of an allergy test, which can be done at home. [2, 3, 10] The drops contain small amounts of specific FDA-approved allergen extracts (such as tree pollen, grass, or pet dander) to which the patient is allergic. [1, 7, 14] By administering two drops under the tongue daily, the therapy works by gradually training the body's immune system to build tolerance to these allergens, thereby addressing the root cause of allergies rather than just masking symptoms. [1, 3] Nectar reports that the allergen concentrations used are equivalent to those in FDA-approved sublingual immunotherapy tablets and are higher than most other allergy drops available in the U.S. [1, 5, 12] Patients may begin to experience symptom relief in 3-6 months, with the goal of achieving long-term immunity in 3-5 years. [2, 12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nectar Allergy Drops.